Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q1 2017 · 10-Q
Revenue$12.34M$12.34M+76.0% vs Q1 2016 Net Income-$1.22M-$1.22MN/M vs Q1 2016 EPS Diluted-$0.09-$0.09N/M vs Q1 2016 Gross Profit$3,301,350+4.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flow-$837,933N/M Margins · derivedGross margin26.8%−18.1 pt vs Q1 2016
Operating margin-5.1%+8.9 pt vs Q1 2016
Net margin-9.9%+6.7 pt vs Q1 2016
ended Mar 31, 2017 · filed May 12, 2017 · 42 d after period end